34
Participants
Start Date
April 22, 2022
Primary Completion Date
April 30, 2025
Study Completion Date
April 30, 2025
Serabelisib
serabelisib administered orally
Insulin Suppressing Diet
3 meals consumed daily (i.e., breakfast, lunch, dinner) and optional snacks provided dependent on caloric needs
Nab paclitaxel
nab-paclitaxel administered intravenously weekly
Memorial Sloan Kettering Cancer Center, New York
Northwell Health, Lake Success
University of Pennsylvania Health System, Perelman Center for Advanced Medicine, Philadelphia
East Carolina University, Greenville
University of Alabama, Birmingham
Community Health Network, Inc., Indianapolis
Medical College of Wisconsin, Milwaukee
Mayo Clinic - Rochester, Rochester
Avera Cancer Institute, Sioux Falls
Oncology Consultants, PA, Houston
Lumi Research, Kingwood
Baptist Hospitals of Southeast Texas, Beaumont
Valkyrie Clinical Trials, Los Angeles
Hoag Memorial Hospital Presbyterian, Newport Beach
Pacific Cancer Specialists, Anaheim
New Jersey Cancer Care, PA, Belleville
Englewood Health, Englewood
Lead Sponsor
Faeth Therapeutics
INDUSTRY